XI'AN, China, July 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng
Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading
developer and producer of plant extracts and pharmaceutical raw materials
for use in pharmaceutical, nutraceutical and food production in China,
announced today that its company information will be made available via
Standard & Poor's Market Access Program, an information distribution
service that enables subscribing publicly traded companies to have their
company information disseminated to users of Standard & Poor's Advisor
Insight. The company information to be made available through this program
includes share price, volume, dividends, shares outstanding, company
financial position, and earnings. Standard & Poor's Advisor Insight is an
Internet-based research engine used by more than 100,000 investment
advisors. A public version of the site is available at
http://www.advisorinsight.com .
In addition, information about companies in Standard & Poor's Market
Access Program will be available via S&P's Stock Guide database, which is
distributed electronically to virtually all major quote vendors. As part of
the program, a full description of Huifeng Bio-Pharmaceutical Technology,
Inc. will also be published in the Daily News section of Standard
Corporation Records, a recognized securities manual for secondary trading
in approximately 38 states under their Blue Sky Laws.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's
Republic of China, develops and produces plant extracts and pharmaceutical
raw materials for use in pharmaceutical, nutraceutical and food production.
It is the leading Chinese producer of rutin and related plant-derived
chemicals in a class called flavonoids, with medicinal and other beneficial
properties. Founded in 2002, Huifeng uses proprietary patented processes to
extract rutin more efficiently than traditional extraction techniques. The
Company is diversifying its product lines through internal development,
acquisition and cooperation with scientific research organizations.
Additional information about Huifeng can be found from their website,
http://www.hfgb.cn .
Company information distributed through the Market Access Program is
based upon information that Standard & Poor's considers to be reliable, but
neither Standard & Poor's nor its affiliates warrant its completeness or
accuracy, and it should not be relied upon as such. This material is not
intended as an offer or solicitation for the purchase or sale of any
security or other financial instrument.
For more information, please contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Daniel Carlson
Primary Capital LLC.
Tel: +1-415-460-1165
Email: DCarlson@PrimaryLLC.com
Standard & Poor's Customer Contact:
Richard Albanese
Tel: +1-212-438-3647
Email: richard_albanese@sandp.com
Standard and Poor's Media Relations Contact:
Michael Privitera
Tel: +1-212-438-6679
Email: michael_privitera@sandp.com
See Also:
- National Council on Disability to Hold Quarterly Board Meeting in Seattle to Learn Issues Affecting People with Disabilities in Pacific Northwest
- Senesco Chooses VGXI to Produce Factor 5A Plasmid
- Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System
- Hooper Holmes Announces Sale of Claims Evaluation Division
- AMERIGROUP Renews Contract with Tennessee
[Via Healthcare]
0 коментарі:
Post a Comment